Using Kaplan–Meier analysis, late-stage NSCLC patients with high expression of VEGFR-2 were found to have a median survival time of 14 months, while late-stage NSCLC patients with low expression had a median survival time of 21 months (Figure 8). Here, KDR is linked to non-small cell lung carcinoma.